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Patients with rectal cancers, due to the unique location of the tumor, have a recurrence pattern distinct from colon cancers.
Advances in adjuvant therapy over the last three decades have played an important role in improving patient outcomes. This
article serves to review the clinical studies that lay the basis for our current standard-of-care treatment of patients with locally
advanced rectal cancer, as well as touch upon future ongoing experimental clinical trials of adjuvant chemoradiation therapy.
1.Introduction
Overonemillionpeoplearediagnosedwithcolorectalcancer
each year world-wide [1]. Patients with rectal cancers com-
prise approximately one-ﬁfth of all patients with colorectal
adenocarcinomas [2]; the unique anatomic location of the
rectum with respect to the colon puts these patients at far
higher risk of local recurrence [3]. Although adenocarci-
noma is the most common cancer pathology of the rectum,
squamous cell [4], adenosquamous [5], carcinoid cancers
[6], and melanomas [7] also arise from the rectum, although
with much lower prevalence. Anatomically the superior
rectum is deﬁned by the expansion of the taenia coli of the
sigmoid colon to form a circular layer of muscle; inferiorly it
is deﬁned by the anorectal line (dentate line) [8]. The
rectum is approximately 10–15 centimeters in length and
endoscopically starts at 3 centimeters from the anal verge,
extending to 15 centimeters, with signiﬁcant person-to-
person variation [9]. Patients with rectal cancer represent a
subset of colorectal adenocarinoma patients that have been
shown to have higher rates of recurrence after surgery alone
when compared with more proximal portions of the colon
secondary to its largely extraperitoneal situation [10]. Given
the high rate of locally recurrent disease, multimodality
therapy with a combination of total mesorectal excision
(TME), radiation and chemotherapy (combined modality
therapy, CMT) has now become the standard-of-care in
locally advanced rectal cancer [11]. This paper seeks to
review the seminal data that supports this approach, as well
as touch on current controversies in the multimodality care
of patients with locally advanced rectal cancer.
2. The Dawn of AdjuvantTherapy in
Rectal Cancer
For many years, surgical resection was the only approach for
patientswithlocallyadvancedrectalcancer.Forpatientswith
stage I disease, this continues to be the deﬁnitive treatment
with a ﬁve-year overall survival (OS) rate of approximately
75% and a 7% or less local recurrence rate; however, patients
with transmural penetration or nodal metastases have a
higher risk of both local and distant recurrence, leading to
inferior survival outcomes [12]. Given the high burden of
local recurrence, eﬀorts were initially placed into incor-
porating radiation therapy into the management of these2 International Journal of Surgical Oncology
patients as a means to improve local control. Chemotherapy
was also incorporated into therapy to address potential
micrometastatic disease (distant failure) as well as a tumor
radiosensitizer [13].
In 1985, the Gastrointestinal Tumor Study Group
(GITSG) published a randomized trial addressing the role of
adjuvant radiation, chemotherapy, and chemoradiation in
the treatment of locally advanced rectal cancer. A total of 227
patientswererandomizedafterreceivingsurgicalresectionto
four diﬀerent groups including: (1) no adjuvant therapy, (2)
adjuvantradiationaloneateither40or48gray(Gy)dose,(3)
adjuvant chemotherapy with semustine and 5-ﬂuorouracil
(5-FU), or (4) adjuvant combined modality therapy (CMT)
with either 40 or 44Gy radiation with concurrent 5-FU
followedbypost-radiation semustineplus5-FU.Atamedian
follow-up time of 80 months, patients in the control group
h a dal o c a lr e c u r r e n c er a t eo f5 5 %c o m p a r e dw i t ho n l y3 3 %
in the adjuvant CMT arm. Additionally, progression-free
survival (PFS) diﬀered signiﬁcantly amongst all four groups
with the CMT arm being the most favorable (P<0.04). In
the initial report, there was a trend towards an OS beneﬁt
when comparing the control group to the CMT group
(P = 0.07) [14]. In 1986, a follow-up report for this study
showed that patients in the CMT group had a 24% estimated
improved survival beneﬁt at seven years (P = 0.005) [15].
After this study, there was still the question as to whether
or not adjuvant CMT was truly superior to adjuvant radia-
tion therapy alone. This was addressed in a prospective study
of 204 post-operative patients with T3, T4 or node-positive
rectal cancer who were randomly assigned to receive either
adjuvant radiation or CMT. The adjuvant radiation arm
was treated with 45 to 50.4Gy, while the combined group
received the same dosage of radiation with concurrent 5-FU.
The CMT group was treated with one cycle of semustine-
plus ﬂuorouracil before and after radiation followed by an
additional cycle of 5-FU. Patients in the radiation alone arm
had an estimated ﬁve-year recurrence of 62.7% compared
with 41.5% in the combination group. (P = 0.0016). More
importantly, there was a 29% reduction in the overall death
rate in the CMT group [11].
3. Chemotherapy versus CMT
As a result of these promising trials, the National Institute
of Health (NIH) published a Consensus Statement in 1990
advocating theuse ofcombinedCMT foradjuvanttreatment
in stage II and III rectal cancers [17]. The National Surgical
Adjuvant Breast and Bowel Project (NSABP) Protocol R-01
trial demonstrated that patients who received adjuvant radi-
ation when compared to surgery alone had an overall reduc-
tion in local recurrence, but no diﬀerence in DFS and OS.
Meanwhile, patients who received adjuvant chemotherapy
had an improvement in DFS and OS when compared with
patientswhoreceivedonlysurgery[18].Giventheseﬁndings,
the NSABP conducted a study, R-02, which randomized 694
patients to receive chemotherapy with or without radiation.
Chemotherapy was given as either a regimen with bolus 5-
FU modulated with leucovorin or with the MOF regimen
which included semustine, vincristine, and 5-FU. Much like
the NSABP Protocol R-01 trial, the addition of radiation to
adjuvantchemotherapydidnotimprovedisease-freesurvival
(P = 0.90) or overall survival (P = 0.89) but did decrease
the ﬁve-year incidence of local relapse from 13 percent to 8
percent (P = 0.02) [19].
4. NeoadjuvantRadiation
Since these trials were unable to demonstrate an OS beneﬁt
with postoperative radiation, many groups started to explore
the use of radiation in the preoperative setting. In 1997, the
SwedishRectalCancerTrialbecametheﬁrsttrialtoshowsur-
vival beneﬁt with the addition of preoperative neoadjuvant
radiation [20]. In this trial, 1,168 patients were randomly
assignedtoreceiveeithersurgeryaloneorpreoperativeshort-
course radiotherapy followed by surgery. The radiation was
givenover5daysforatotalof25Gywithinoneweekpriorto
surgicalresection.Patientsinthestudyintheradiationgroup
had a much lower 5-year local recurrence rate of 11% versus
27% (P<0.001). Meanwhile, the ﬁve-year survival rate was
58% in the radiation group compared with only 48% in the
surgery alone group (P = 0.004) [21]. Long-term followup
continued to show an OS beneﬁt at 13 years [22].
AroundthetimethattheSwedishRectalCancerTrialwas
being conducted, total mesorectal excision (TME) was being
established as the gold-standard for surgical resection in
rectal cancer [22]. The impressive results of TME called into
question many of the previous neoadjuvant and adjuvant
trials that did not utilize the optimal surgical method. The
Dutch Colorectal Cancer Group (DCCG) addressed this by
conducting a trial similar to the Swedish Rectal Cancer
Trial comparing short-course radiotherapy (25Gy over 5
fractions) with TME versus TME alone. At two years, the
rates of local recurrence were 2.4% in the radiation group
versus 8.2 percent in the TME only group (P<0.001) [23].
At ﬁve years, local recurrence rates were 5.6 percent versus
10.9 percent (P<0.001), but overall survival was only 64.2%
in the radiation with TME group versus 63.5% in the TME
only group (P = 0.902) [24].
5. NeoadjuvantCMT
Given the potential of neoadjuvant radiation and the prior
success of postoperative chemoradiation, the next step in the
treatment of locally advanced rectal adenocarcinoma was the
exploration of neoadjuvant CMT in the preoperative setting
[25]. The ﬁrst of these was the German Rectal Cancer Study
Group, which compared neoadjuvant CMT with adjuvant
CMT in patients with T3, T4, or node-positive disease. The
study enrolled 823 patients from 1995 to 2002. Patients
assigned to the neoadjuvant CMT group received ﬁve weeks
of preoperative chemoradiation (50.4Gy given in 18Gy per
day over 28 fractions, ﬁve days per week). Patients were also
given 5-FU as a protracted venous infusion at 1000mg/m2
per day for ﬁve days on weeks one and ﬁve. A TME was then
performed within six weeks of completion of neoadjuvant
CMT. Patients in the adjuvant arm started four weeks after
surgery and received the same schedule of CMT, with the
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postoperative 5-FU at 500mg/m2 per day for ﬁve days over
four weeks. The study found no diﬀerence in 5-year OS
betweenthetwogroups(76%fortheneoadjuvantgroupand
74% for the adjuvant group, P = 0.8025). However, there
was a lower local recurrence rate in the neoadjuvant group,
6%comparedto13% (P = 0.006). Additionally, itwasfound
that the neoadjuvant group had signiﬁcantly less long-term
toxicities, particularly with regards to diarrhea, small bowel
obstruction, and strictures at the anastomotic site [25].
The European Organization for Research and Treatment
of Cancer (EORTC) published the results of Trial 22921
which also attempted to assess the addition of chemotherapy
to preoperative radiotherapy. This trial randomized 1,011
patientstofourdiﬀerentarms:(a)preoperativeradiotherapy,
(b) preoperative CMT, (c) preoperative radiotherapy with
postoperative chemotherapy, or (d) preoperative CMT with
postoperative chemotherapy. Radiation was given as 45Gy
delivered over 25 fractions; the 5-FU was given as a
continuous infusion, modulated by leucovorin, for ﬁve days
weeks one and ﬁve for the arms receiving preoperative CMT.
Postoperative chemotherapy was given every three weeks
for four cycles with the same regimen used preoperatively.
The primary endpoint was OS between the two preoperative
modalities and the two postoperative modalities. Ultimately,
there was no diﬀerence in OS between the two groups
that received preoperative radiation versus the two groups
that received preoperative chemoradiation [26]. However,
the group that did not receive any chemotherapy had a 5-
year local recurrence of 17.1%. This was signiﬁcantly higher
than the preoperative CMT, the preoperative radiation with
postoperative chemotherapy, and the preoperative CMT
with postoperative chemotherapy groups, which had local
recurrence rates of 8.7%, 9.6%, and 7.6%, respectively (P =
0.002) [26]. The trial was not designed to detect a diﬀerence
inOSbetweenthefourgroups,sothiswasnotreported.Also
of note, the trial ran for six years before it was required for
patients to have a TME; thus, less than half of the patients
were documented as having a TME.
The NSABP R-03 trial attempted to solidify the role
neoadjuvant chemoradiotherapy as the treatment of choice
for patients with stage II and III rectal cancer; in this study
267 patients were randomly assigned to either neoadjuvant
CMT or adjuvant chemoradiation. Patients in the neoadju-
vant group initially received a bolus of 5-FU with leucovorin
once per week for six weeks. This was followed by radiation
given as 45Gy over 25 fractions with a 5.4Gy boost. 5-FU
and leucovorin were given on days 1–5 and days 21–25 of
radiation. Patients then proceeded to surgery followed by 24
more weeks of weekly 5-FU and leucovorin. Patients in the
adjuvant group followed the same treatment course with
six weeks of chemotherapy, ﬁve weeks of CMT, and 24
weeksofchemotherapyallfollowinginitialsurgery.Five-year
disease-free survival (DFS) for the neoadjuvant group was
64.7 percent compared with 53.4 percent for the adjuvant
group (P = 0.011) [27]. Additionally, there was observed
a trend towards superior 5-year OS that was seen with
74.7% versus 65.6%, respectively (P = 0.65) [27]. Another
interesting ﬁnding in this study was the 15% of patients
in the neoadjuvant CMT group who obtained a complete
pathologic response. In this small subset of patients, none of
them had a recurrence. In this study it was not a requirement
that all patients in this trial undergo a TME, which may have
potentially confounded some of the results.
6.OptimizingNeoadjuvantTreatment
While questions still remain, for the most part, the results
have established neoadjuvant CMT followed TME as the
standard treatment in stage II and III rectal cancer with no
contraindications to surgery or CMT. Subsequent trials have
now tried to focus on optimizing both the length and types
of chemotherapy and radiation used to improve survival and
decrease toxicities.
6.1. Semustine. Many of the initial trials that favored adju-
vant chemoradiation using 5-FU and semustine had con-
cerns over the long-term toxic eﬀects of semustine. In the
ﬁrst GITSG study [11], one patient who received semustine
developed acute myelogenous leukemia (AML). The con-
cerns over this toxicity led two trials to evaluate the beneﬁt of
adding semustine to 5-FU and radiation. Both studies found
no diﬀerences in OS and semustine was ultimately excluded
from future clinical studies.
6.2. 5-FU. The use of continuous infusion 5-FU over bolus
5-FU has become the standard of care in the perioperative
treatment of rectal cancers primarily for its advantageous
toxicity proﬁle. In rectal cancer, the North Central Cancer
Center Treatment Group (NCCTG) conﬁrmed this by com-
paring adjuvant CMT with bolus 5-FU versus protracted
venous infusion (PVI) [28]. Four-year relapse-free survival
(RFS) was 53% in the bolus group and 63% in the continu-
ous infusion group (P = 0.01), and four-year OS was 60%
in the bolus group as compared with 70% in the continuous
infusion group (P = 0.005) [28]. There was also signiﬁcantly
more diarrhea seen in the continuous infusion group versus
more leucopenia in the bolus group.
6.3.Capecitabine. ThebackbonesystemictherapyinCMTin
the past has been 5-FU; while initially given as bolus therapy
over 30 minutes, both prior to, with radiation, and following
CMT, a randomized study demonstrated superiority of PVI
5-FU, in terms of decrease local relapse and improved
OS [29]. Given the convenience of administration of the
oral ﬂuropyrimidines, and the fact that their administra-
tion which had similar pharmacokinetics to PVI 5-FU,
capecitabine was studied in combination with radiation in
the neoadjuvant CMT in rectal cancer patients. Phase I
studies determined that the recommended phase II dose
of capecitabine when combined with 50.4Gy radiation
preoperativelywas1800mg/m2 dailygivenorallyintwodaily
divided doses [30].
For most medical oncologists, capecitabine has become
an acceptable equivalent alternative to 5-FU in the peri-
operative CMT treatment of rectal cancer. Much of this
approach is extrapolated from the demonstrated eﬃcacy of
capecitabine in the adjuvant treatment of colon cancer [31].4 International Journal of Surgical Oncology
Two randomized phase III studies evaluated the eﬃcacy of
capecitabine as a neoadjuvant radiosensitizing agent. The
German trial compared the use of 5-FU to capecitabine in
the perioperative CMT setting. Patients in the capecitabine
arm received preoperative chemoradiation with 50.4Gy and
capecitabine 1,650mg/m2 ( i nt w od i v i d e dd o s e s )o nd a y s1
through 38 plus capecitabine 2,500mg/m2 days 1–14 every
21 days for ﬁve additional cycles. Patients were also assigned
to receive the ﬁve additional cycles of capecitabine either
before or after TME. Patients assigned to the 5-FU arm
received neoadjuvant chemoradiation with 50.4Gy and
either 5-FU 225mg/m2 daily or given as 1,000mg/m2 on
weeks one and ﬁve of radiation. Patients were also given
four additional cycles of bolus 5-FU 500mg/m2 for ﬁve days
every 28 days. This was given either in the preoperative or
postoperative setting. The ﬁve-year OS rate was 75.7% for
the capecitabine group and 66.6% for the 5-FU group. This
was signiﬁcant for noninferiority (P = 0.0004) with a trend
towards signiﬁcance for superiority in favor of capecitabine
(P = 0.053) [32].
A second randomized study, the NSABP R-04 trial,
compared the use of capecitabine to continuous infusion 5-
FU (both with or without oxaliplatin) during CMT. 5-FU
was given as a 225mg/m2 daily PVI during radiation and
capecitabine was given at 1650mg/m2 orally in two divided
doses daily on the days of radiation only. No diﬀerences were
seen with regards to pathologic complete response, surgical
downstaging, or sphincter-saving surgery [33]. Local recur-
rence and overall survival have yet to be reported.
6.4. Oxaliplatin. Given the eﬃcacy of oxaliplatin in the adju-
vant [34] and metastatic [35] treatment of colon cancer,
several recent trials have assessed the use of oxaliplatin in the
perioperative treatment of rectal cancer. The Studio Terapia
Adiuvante Retto (STAR)-01 trial has so far demonstrated a
signiﬁcant increase in toxicity, mainly diarrhea, without a
beneﬁtinlocaltumorresponse[36].Similarly,theNSABPR-
04 trial evaluated the addition of oxaliplatin with chemora-
diation and found no improvement in pathologic complete
response, surgical downstaging, or sphincter-saving surgery
but did see a signiﬁcant increase in grade 3 and 4 diarrhea
(P<0.0001) [33].
The German CAO/ARO/AIO-04 Trial showed that
patients who received oxaliplatin with 5-FU during radiation
had a pathologic complete response of 17.6% as compared
with 13.1% (P = 0.033) for the group that received 5-
FU alone during radiation [37]. The ACCORD 12/0405-
Prodige Trial, which compared capecitabine with or without
oxaliplatin during chemoradiation, demonstrated a simi-
lar statistical trend towards beneﬁt with oxaliplatin, with
pathologic complete response favoring the group receiving
oxaliplatin, 13.9% compared to 19.2% (P = 0.09) [38].
Given no prospect clinical trial has demonstrated a survival
advantage with the addition of oxaliplatin to CMT, preop-
erative oxaliplatin is currently not standard-of-care. Longer
term followup for all of these studies is needed to evaluated
DFS and OS before the eﬃcacy of preoperative oxaliplatin
can be assessed.
7. The Role of Additional Chemotherapy after
Chemoradiation and Surgery
To date, there have not been any trials that have explored
the use of further additional chemotherapy in rectal cancer
after neoadjuvant chemotherapy and surgical resection.
For the most part, medical oncologists use data from the
adjuvant chemotherapy trials in stage II and III colon cancer
as evidence and typically aim for a total of six months
of perioperative treatment. The Multicenter International
Study of Oxaliplatin/5-Fluorouracil/Leucovorin (FOLFOX)
in the Adjuvant Treatment of Colon Cancer (MOSAIC)
Investigators published the deﬁnitive trial that established
the addition of oxaliplatin to 5-FU and leucovorin, the
FOLFOX regimen, as the standard of care in the adjuvant
setting [39]. Capecitabine with oxaliplain (CapeOx) has
been shown to be superior to bolus 5-FU modulated by
leucovorin (Mayo regimen) [16]. An equilvelance phase
III study comparing FOLFOX with CapeOx is currently
ongoing; safety data from this adjuvant trial suggest CapeOx
isreasonablywelltolerated[16].Itisgenerallyrecommended
that patients with stage III or high-risk stage II colon cancer
receive additional postoperative systemic ﬂuropyrimidine-
based adjuvant chemotherapy [11]. However, at this point,
it is unknown whether or not patients with stage II rectal
cancer truly beneﬁt from additional adjuvant chemotherapy
or if there is a subset of these patients who do not beneﬁt
from further treatment, similar to what is observed with the
standard risk patients with stage II colon cancer.
8. Monoclonal Antibody Therapy in
Neoadjuvant Treatment of Rectal Cancer
Monoclonal antibody therapies directed at circulating vas-
cular endothelial growth factor (VEGF) and against cell
receptor epidermal growth factor (EGFR) have become
standard treatments in advanced colorectal cancer [40–42].
The anti-VEGF monoclonal antibody bevacizumab has been
combined with capecitabine in a neoadjuvant CMT phase II
single center study of 32 patients, with acceptable tolerance
andapathologic completeresponse rateof 32%[43].Similar
results were observed in another phase I/II single center
trial, with promising clinical downstaging and a complete
pathologic response rate of 23% (5 of 22 patients) [44].
Bevacizumab has also been combined with both oxaliplatin
and capecitabine, in CMT; six of 25 (24%) patients achieved
a complete pathologic response although there was noted
to be signiﬁcant gastrointestinal toxicity [45]. At this time
no phase III trials evaluating the preoperative eﬃcacy of
bevacizumab are actively enrolling. Bevacizumab, cetux-
imab, and capecitabine are being combined with radiation
preoperatively, in an ongoing current trial of KRAS non
mutant rectal cancer patients [46]. The EXPERT-C trail
was a randomized phase II study of preirradiation CAPOX
followed by radiation therapy with capecitabine followed by
TME, followed by postirradiation CAPOX; the experimental
arm involved weekly concurrent monoclonal anti-EGFR
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patients 90 (60%) were KRAS and BRAF non mutant.
In this subset of patients the three-year OS was superior
in the cetuximab-treated arm (96% versus 81%, P =
0.035), although there were no diﬀerences in the pathologic
complete response rate [47].
9. FutureCombined ModalityApproachesto
LocallyAdvancedRectalCancer
It is recognized that cancers in the upper one-third of the
rectal have a lower risk of local recurrence when treated with
surgery alone [48]; thus it is possible that some cancers,
based on their anatomic location, may not beneﬁt from
the addition of radiation to chemotherapy and might be
adequately treated with perioperative chemotherapy alone.
However, this would have to be conﬁrmed by randomized
clinical trials before altering the current standard-of-care.
A four-stage combined modality approach (chemotherapy,
chemoradiation, surgery, and postoperative chemotherapy),
as demonstrated by the EXPERT-C trial referenced above
[47], is also being actively evaluated. The duration of
preoperativechemotherapyisalsobeingaddressedinstudies;
a three arm trial of chemoradiation, versus chemoradiation
and two cycles FOLFOX chemotherapy, versus chemoradi-
ation and 4 cycles FOLFOX chemotherapy, demonstrated a
higher pathologic complete response rate associated with the
more preoperative FOLFOX chemotherapy, without increas-
ing the surgical complication rates [49]. Whether or not this
approach will lead to higher OS rates is currently unclear.
10. Conclusions
The multidisciplinary management of rectal cancer, with
the incorporation of radiation and chemotherapy into the
treatment plan, has had a signiﬁcant impact on survival
outcomes. Future approaches will likely tailor therapies and
approaches based upon the anatomic location of the tumor,
the molecular features, and possibly the pathologic response
toneoadjuvanttherapy.While5-FUandcapecitabineremain
the standard therapy for combination with radiation, future
studies may deﬁne a role for subsets of patients who beneﬁt
from the addition of oxaliplatin and 5-FU or capecitabine
combined with radiation. The optimal preoperative dose
of radiation, treatment schedule, and type of radiation
treatment planning techniques continue to be evaluated
prospectively in clinical trials. Future signiﬁcant advances
in systemic therapies hold the prospect of decreasing the
necessity of surgery or radiation in rectal cancer.
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